Complement Inhibition: Attacking the Overshooting Inflammation @Fter Traumatic Brain Injury (CIAO@TBI)
A Phase II Trial on the Safety and Efficacy of C1 Inhibitor for the Acute Management of Severe Traumatic Brain Injury
Sponsor: Leiden University Medical Center
Listed as NCT04489160, this PHASE2 trial focuses on Trauma, Head and Traumatic Brain Injury and remains ongoing. Sponsored by Leiden University Medical Center, it has been updated 7 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
7 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
-
Oct 2021 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 2 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Not Yet Recruiting PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Leiden University Medical Center
- Netherlands Brain Foundation
- Takeda
For direct contact, visit the study record on ClinicalTrials.gov .